Use the search parameters below to filter talks:

Calendar
Calendar

2010 - TTS International Congress (Vancouver)

Clinical Immunosuppression Kidney late
15 August 2010  /  00:00 - 00:01

Mycophenolic Acid (MPA) Dose Reductions Result in Poor Long Term Renal Allograft Survival: Comparison Between Sodium Mycophenolate (SMPA) and Mycophenolate Mofetil (MMF)

Presenter: Mark Reza Laftavi, Buffalo, United States

- Mycophenolic Acid (MPA) Dose Reductions Result in Poor Long Term Renal Allograft Survival: Comparison Between Sodium Mycophenolate (SMPA) and Mycophenolate Mofetil (MMF)

Presenter: Mark Reza Laftavi, Buffalo, United States

Impact of the CYP3A5 *1/*3 Alleles on the Pharmacokinetics of Two Tacrolimus Formulations after Renal Transplantation

Presenter: Philip Burgwinkel, Berlin, Germany

- Impact of the CYP3A5 *1/*3 Alleles on the Pharmacokinetics of Two Tacrolimus Formulations after Renal Transplantation

Presenter: Philip Burgwinkel, Berlin, Germany

Gastrointestinal discomfort in kidney transplant recipients receiving enteric coated mycophenolic acid

Presenter: Matthias Raggi, Stuttgart, Germany

- Gastrointestinal discomfort in kidney transplant recipients receiving enteric coated mycophenolic acid

Presenter: Matthias Raggi, Stuttgart, Germany

Difference in clinical outcomes with early or delayed introduction of everolimus in renal transplant recipients

Presenter: Cesar Agost Carreño, Buenos Aires, Argentina

- Difference in clinical outcomes with early or delayed introduction of everolimus in renal transplant recipients

Presenter: Cesar Agost Carreño, Buenos Aires, Argentina

A trial of mycophenolate monotherapy in HLA identical sibling renal transplantation

Presenter: William Burlingham, Madison, United States

- A trial of mycophenolate monotherapy in HLA identical sibling renal transplantation

Presenter: William Burlingham, Madison, United States

Conversion from Prograft® to Advagraf® among kidney transplant recipients results in sustained decrease in tacrolimus exposure

Presenter: Daniel Abramowicz, Anderlecht, Belgium

- Conversion from Prograft® to Advagraf® among kidney transplant recipients results in sustained decrease in tacrolimus exposure

Presenter: Daniel Abramowicz, Anderlecht, Belgium

Immune Regulation and Tolerance I
15 August 2010  /  00:00 - 00:01

Induced CD4+CD25+Foxp3+ regulatory T cells and impaired development of CD8+CD44+CD62L+ memory T cells promote specific tolerance to cardiac allografts following Rapamycin treatment

Presenter: Peter Urbanellis, Toronto, Canada

- Induced CD4+CD25+Foxp3+ regulatory T cells and impaired development of CD8+CD44+CD62L+ memory T cells promote specific tolerance to cardiac allografts following Rapamycin treatment

Presenter: Peter Urbanellis, Toronto, Canada

Tribbles-1 is expressed by regulatory T cells and interacts with FOXP3

Presenter: Jean-Paul Soulillou, Nantes cedex, France

- Tribbles-1 is expressed by regulatory T cells and interacts with FOXP3

Presenter: Jean-Paul Soulillou, Nantes cedex, France

De Novo expression of CD8 on CD4+CD8-CD25+Foxp3+ T regulatory cells, activated by alloantigen and IL-2, identifies alloantigen specific T regulatory cells.

Presenter: Bruce Hall, Eveleigh, Australia

- De Novo expression of CD8 on CD4+CD8-CD25+Foxp3+ T regulatory cells, activated by alloantigen and IL-2, identifies alloantigen specific T regulatory cells.

Presenter: Bruce Hall, Eveleigh, Australia

The direct alloreactivity pathway is more susceptible to regulation by nTreg than the indirect pathway.

Presenter: Grégory Noël, Laval, Canada

- The direct alloreactivity pathway is more susceptible to regulation by nTreg than the indirect pathway.

Presenter: Grégory Noël, Laval, Canada

The Janus kinase inhibitor CP-690,550 preserves the suppressive activity of human CD4+CD25brightFoxP3+ regulatory T cells and strongly inhibits effector T cells

Presenter: Carla Baan, Rotterdam, Netherlands

- The Janus kinase inhibitor CP-690,550 preserves the suppressive activity of human CD4+CD25brightFoxP3+ regulatory T cells and strongly inhibits effector T cells

Presenter: Carla Baan, Rotterdam, Netherlands

Human CD4+FOXP3+ T regulatory cells produce CXCL8 and recruit inflammatory immune cells

Presenter: Megan Himmel, Vancouver, Canada

- Human CD4+FOXP3+ T regulatory cells produce CXCL8 and recruit inflammatory immune cells

Presenter: Megan Himmel, Vancouver, Canada

Clinical and Ethical Aspects of Living Donor Transplantation
15 August 2010  /  00:00 - 00:01

Racial Disparities in Living Donor Rates: What Predicts the Likelihood of Receiving a Donor?

Presenter: Keren Ladin, Boston, United States

- Racial Disparities in Living Donor Rates: What Predicts the Likelihood of Receiving a Donor?

Presenter: Keren Ladin, Boston, United States

Increasing kidney function in living kidney donors proceeds for a long time after nephrectomy

Presenter: John Söfteland, Göteborg, Sweden

- Increasing kidney function in living kidney donors proceeds for a long time after nephrectomy

Presenter: John Söfteland, Göteborg, Sweden

Seven Non-simultaneous Extended Altruistic Donor (NEAD) Chains

Presenter: Michael Rees, TOLEDO, United States

- Seven Non-simultaneous Extended Altruistic Donor (NEAD) Chains

Presenter: Michael Rees, TOLEDO, United States

Long-term outcomes of living kidney donors – a single centre experience of 29 years

Presenter: kwok hong chu, hong kong, People's Republic of China

- Long-term outcomes of living kidney donors – a single centre experience of 29 years

Presenter: kwok hong chu, hong kong, People's Republic of China

Outcomes for donors and recipients following kidney donation from living donors, 65 years and older.

Presenter: Belinda Bennett, Parkville, Australia

- Outcomes for donors and recipients following kidney donation from living donors, 65 years and older.

Presenter: Belinda Bennett, Parkville, Australia

Age does not affect survival of kidneys from elderly living donors

Presenter: Mirjam Laging, Rotterdam, Netherlands

- Age does not affect survival of kidneys from elderly living donors

Presenter: Mirjam Laging, Rotterdam, Netherlands

Is Living Donor Outcome Effected By Leaving Behind a Kidney With Multiple Arteries?

Presenter: Michael Rizzari, Minneapolis, United States

- Is Living Donor Outcome Effected By Leaving Behind a Kidney With Multiple Arteries?

Presenter: Michael Rizzari, Minneapolis, United States

Clinical Immunosuppression Kidney early
15 August 2010  /  00:01 - 00:01

The influence of immunosuppressive therapy based on calcineurin inhibitors on living kidney transplantation outcomes

Presenter: Alexey Sharshatkin, Moscow, Russian Federation

- The influence of immunosuppressive therapy based on calcineurin inhibitors on living kidney transplantation outcomes

Presenter: Alexey Sharshatkin, Moscow, Russian Federation

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi